In fact, according to the US Preventive Services Task Force, screening of prostate cancer using the prostate‐specific antigen (PSA) presents grade C of evidence for men aged 55–69 years (meaning that the decision should be individualized), and grade D for men older than 69 years, which has led to a reduction in the screening.24 This evidence concerns the gene KLK3 and prostate cancer.